Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A single-centre Shanghai RCT found a family-support self-management programme raised self-management behaviour scores in type 2 diabetes, while HbA1c and other biochemical markers did not improve significantly. PICO summary and expert commentary.
A secondary analysis of the CORDIOPREV trial reports that a lower baseline neutrophil count is associated with type 2 diabetes remission in patients with coronary heart disease following a Mediterranean diet. PICO summary and expert commentary.
A within-trial economic evaluation of the CIC-PDD integrated care model for type 2 diabetes with depressive symptoms reports a cost per QALY around $7,400 to $7,900. PICO summary and expert commentary.
DIAMONDS is a published protocol for a randomised trial testing a supported diabetes self-management programme in adults with type 2 diabetes and severe mental illness; no results are reported yet. PICO summary and expert commentary.
A 3-month randomised controlled trial found that a 10-hour time-restricted eating window did not alter mitochondrial bioenergetics in blood cells of adults at high type 2 diabetes risk. PICO summary and expert commentary.
A decentralized n-of-1 crossover trial found dapagliflozin lowered the urine albumin-to-creatinine ratio by 15.1% versus placebo over 1-week periods in 20 adults with type 2 diabetes, while demonstrating reliable remote sampling. PICO summary and expert commentary.
A 2-year cluster RCT in India found a family-based, health-worker-delivered programme cut adult body weight by an adjusted 2.61 kg versus enhanced usual care. PICO summary and expert commentary.
A secondary analysis of the EARLIER trial found that diabetes plus CKD predicted worse cardiovascular outcomes in acute heart failure, while eplerenone's effects appeared consistent across subgroups. PICO summary and expert commentary.
A single-arm extension found HbA1c was sustained over 30 weeks in adults with type 1 diabetes who switched to inhaled technosphere insulin plus degludec. PICO summary and expert commentary.
A 13-week single-arm switch study tested inhaled technosphere insulin plus degludec against participants' own baseline in 49 adults with type 1 diabetes. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
